Rafael Holdings, Inc. (NYSE:RFL) Short Interest Up 26.3% in March

Rafael Holdings, Inc. (NYSE:RFL) saw a large growth in short interest during the month of March. As of March 15th, there was short interest totalling 121,900 shares, a growth of 26.3% from the February 28th total of 96,500 shares. Currently, 0.6% of the shares of the stock are short sold. Based on an average trading volume of 36,200 shares, the days-to-cover ratio is currently 3.4 days.

Rafael Price Performance

Shares of Rafael stock remained flat at $1.87 on Tuesday. The stock had a trading volume of 20,098 shares, compared to its average volume of 30,925. Rafael has a 12 month low of $1.29 and a 12 month high of $2.50. The stock has a market cap of $46.59 million, a price-to-earnings ratio of -1.12 and a beta of 1.15. The business has a fifty day simple moving average of $1.98 and a two-hundred day simple moving average of $1.92.

Rafael (NYSE:RFL) last released its earnings results on Thursday, March 13th. The company reported ($0.06) earnings per share (EPS) for the quarter. The company had revenue of $0.08 million during the quarter. Rafael had a negative return on equity of 53.71% and a negative net margin of 5,707.03%.

Institutional Investors Weigh In On Rafael

A hedge fund recently raised its stake in Rafael stock. Geode Capital Management LLC raised its position in Rafael Holdings, Inc. (NYSE:RFL) by 24.8% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 148,068 shares of the company’s stock after acquiring an additional 29,448 shares during the period. Geode Capital Management LLC owned about 0.60% of Rafael worth $287,000 as of its most recent SEC filing. 11.30% of the stock is owned by institutional investors and hedge funds.

Rafael Company Profile

Rafael Holdings, Inc primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells.